Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy
Kabashima, A.; Kitagawa, D.; Nakamura, T.; Kondo, N.; Teramoto, S.; Saito, G.; Funahashi, T.; Adachi, E.; Ikeda, Y.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1716-1718
2014
ISSN/ISBN: 0385-0684 PMID: 25731306 Document Number: 671868
A 63-year-old woman underwent a low anterior resection for rectal cancer in 2002.A n anastomotic recurrence was diagnosed in July 2011.S he rejected the possibility of colostomy as radical surgery.Chemotherapy consisting of capecitabine+ oxaliplatin (XELOX) or folinic acid, fluorouracil, and oxaliplatin (FOLFOX6) + bevacizumab were not possible because of high costs. In view of the lower costs and the potential for ambulation, S-1 monotherapy was started. After 3 months, a reduction in the recurrent lesion was observed.After 19 months, the recurrent lesion revealed a scar, which was judged by biopsy to be Group 1.We had achieved a pathological complete response (CR).The standard treatment for recurrent colon cancer is surgical resection or multidrug chemotherapy. However, in view of a patient's quality of life (QOL), S-1 monotherapy may be considered as a potential therapy.